FGFR2 and cholangiocarcinoma: Furthermore, based on the results of FOENIX trials, futibatinib was approved by FDA this year for the treatment of locally advanced or metastatic cholangiocarcinoma whose tumours harbor an FGFR2 rearrangement or fusion [125].